EQRx, Inc. (NASDAQ:EQRX – Get Rating) traded down 10% on Thursday . The company traded as low as $4.84 and last traded at $4.84. 45,638 shares traded hands during mid-day trading, a decline of 98% from the average session volume of 1,836,906 shares. The stock had previously closed at $5.38.
Analyst Upgrades and Downgrades
A number of research firms have recently issued reports on EQRX. The Goldman Sachs Group assumed coverage on shares of EQRx in a research note on Monday, June 13th. They set a "buy" rating and a $8.00 price objective on the stock. JPMorgan Chase & Co. began coverage on EQRx in a research note on Tuesday, August 16th. They set a "neutral" rating and a $5.50 target price for the company. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $6.37.
Get EQRx alerts:EQRx Stock Down 11.5 %
The business's 50 day moving average is $5.10 and its 200-day moving average is $4.60.
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of the company. Advisor Group Holdings Inc. acquired a new stake in shares of EQRx during the 4th quarter valued at approximately $67,000. TD Asset Management Inc. bought a new position in EQRx in the 4th quarter worth about $1,209,000. Qube Research & Technologies Ltd acquired a new stake in shares of EQRx in the fourth quarter valued at approximately $1,951,000. MYDA Advisors LLC acquired a new position in shares of EQRx during the fourth quarter worth approximately $136,000. Finally, Casdin Capital LLC bought a new position in EQRx in the 4th quarter worth approximately $269,579,000. Institutional investors own 80.38% of the company's stock.EQRx Company Profile
(Get Rating)
EQRx, Inc, a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC.
Featured Stories
- Get a free copy of the StockNews.com research report on EQRx (EQRX)
- Why Medical Products Maker Repligen May Be A Potential Buy
- At 10%, Is Arbor Realty Trust Dividend Worth It?
- Investors Should Tune Into RF Industries
- 2 Reasons Netflix Might Have Just Bottomed Out
- Murphy USA Outperforming Other Mid-caps, But Is It A Buy Now?
Receive News & Ratings for EQRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EQRx and related companies with MarketBeat.com's FREE daily email newsletter.